Intensity Therapeutics (INTS) Change in Interest Receivables (2023 - 2024)
Intensity Therapeutics' (INTS) quarterly Change in Interest Receivables came in at $17000.0 in Q3 2024, down 84.68% YoY from $111000.0 in Q4 2023, and down 55.26% on a QoQ basis from $38000.0 in Q2 2024.
Intensity Therapeutics (INTS) Change in Interest Receivables (2023 - 2024) Analysis & Trends
Intensity Therapeutics (INTS) has 2 years of Change in Interest Receivables data on file, last reported at $17000.0 in Q3 2024.
- Quarterly Change in Interest Receivables fell 84.68% year-over-year to $17000.0 in Q3 2024, while the trailing twelve-month figure through Jun 2025 was $17000.0 (down 94.59% YoY) and the FY2024 annual result came in at $134000.0, down 31.98% from the prior year.
- Change in Interest Receivables slipped to $17000.0 in Q3 2024, from $38000.0 in the prior quarter.
- In the past five years, Change in Interest Receivables ranged from a high of $111000.0 in Q3 2023 to a low of $17000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Interest Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | - |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | - |
| 10 | Intensity Therapeutics | 13.06 Mn | 13.06 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 17,000.00 |
| Jun 30, 2024 | 38,000.00 |
| Mar 31, 2024 | 79,000.00 |
| Dec 31, 2023 | 86,000.00 |
| Sep 30, 2023 | 111,000.00 |